dld 1 Search Results


dld 1  (ATCC)
99
ATCC dld 1
Dld 1, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dld 1/product/ATCC
Average 99 stars, based on 1 article reviews
dld 1 - by Bioz Stars, 2026-06
99/100 stars
  Buy from Supplier
human colon cancer cell lines  (ATCC)
96
ATCC human colon cancer cell lines
Human Colon Cancer Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human colon cancer cell lines/product/ATCC
Average 96 stars, based on 1 article reviews
human colon cancer cell lines - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier
dld1  (DSMZ)
94
DSMZ dld1
( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and <t>DLD1</t> (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.
Dld1, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dld1/product/DSMZ
Average 94 stars, based on 1 article reviews
dld1 - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier
france n a dld 1 flp  (Institut Curie)
86
Institut Curie france n a dld 1 flp
( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and <t>DLD1</t> (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.
France N A Dld 1 Flp, supplied by Institut Curie, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/france n a dld 1 flp/product/Institut Curie
Average 86 stars, based on 1 article reviews
france n a dld 1 flp - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
human colon carcinoma cell line caco-2  (BioResource International Inc)
90
BioResource International Inc human colon carcinoma cell line caco-2
( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and <t>DLD1</t> (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.
Human Colon Carcinoma Cell Line Caco 2, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human colon carcinoma cell line caco-2/product/BioResource International Inc
Average 90 stars, based on 1 article reviews
human colon carcinoma cell line caco-2 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
dld-1 90102540  (European Collection of Authenticated Cell Cultures)
90
European Collection of Authenticated Cell Cultures dld-1 90102540
( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and <t>DLD1</t> (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.
Dld 1 90102540, supplied by European Collection of Authenticated Cell Cultures, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dld-1 90102540/product/European Collection of Authenticated Cell Cultures
Average 90 stars, based on 1 article reviews
dld-1 90102540 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
dld1 colon cancer cell line  (Link Genomics Inc)
90
Link Genomics Inc dld1 colon cancer cell line
( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and <t>DLD1</t> (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.
Dld1 Colon Cancer Cell Line, supplied by Link Genomics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dld1 colon cancer cell line/product/Link Genomics Inc
Average 90 stars, based on 1 article reviews
dld1 colon cancer cell line - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
dld1 cells expressing hgpr40  (DiscoverX corporation)
90
DiscoverX corporation dld1 cells expressing hgpr40
( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and <t>DLD1</t> (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.
Dld1 Cells Expressing Hgpr40, supplied by DiscoverX corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dld1 cells expressing hgpr40/product/DiscoverX corporation
Average 90 stars, based on 1 article reviews
dld1 cells expressing hgpr40 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
human colon carcinoma dld1 cells  (JCRB Cell Bank)
90
JCRB Cell Bank human colon carcinoma dld1 cells
( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and <t>DLD1</t> (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.
Human Colon Carcinoma Dld1 Cells, supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human colon carcinoma dld1 cells/product/JCRB Cell Bank
Average 90 stars, based on 1 article reviews
human colon carcinoma dld1 cells - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
dld-1 cell line  (Johns Hopkins HealthCare)
90
Johns Hopkins HealthCare dld-1 cell line
( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and <t>DLD1</t> (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.
Dld 1 Cell Line, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dld-1 cell line/product/Johns Hopkins HealthCare
Average 90 stars, based on 1 article reviews
dld-1 cell line - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
dld1 cells  (MetaCell Inc)
90
MetaCell Inc dld1 cells
( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and <t>DLD1</t> (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.
Dld1 Cells, supplied by MetaCell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dld1 cells/product/MetaCell Inc
Average 90 stars, based on 1 article reviews
dld1 cells - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
dld-1 cells  (clea japan inc)
90
clea japan inc dld-1 cells
( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and <t>DLD1</t> (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.
Dld 1 Cells, supplied by clea japan inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dld-1 cells/product/clea japan inc
Average 90 stars, based on 1 article reviews
dld-1 cells - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and DLD1 (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.

Journal: Science Advances

Article Title: Microrobotic copper-rich electrochemical interfacing for targeted cancer theranostics in the gut

doi: 10.1126/sciadv.aeb5934

Figure Lengend Snippet: ( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and DLD1 (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.

Article Snippet: Human GI cancer cell lines—including a colorectal adenocarcinoma cell lines HT-29 [American Type Culture Collection (ATCC)], LS174 (DSMZ), and DLD1 (DSMZ); a colorectal carcinoma cell line HCT116 (LGC Standards); a duodenal adenocarcinoma cell line HuTu 80 (ATCC); a pancreatic carcinoma cell line PANC-1 (DSMZ); a gastric adenocarcinoma cell line NCI-N87 (ATCC); an intestinal carcinoma cell line (Caco-2); and a colon epithelial cell line NCM460 (INCELL)—were purchased from each supplier and cultured according to adequate protocols.

Techniques: In Vitro, Immunofluorescence, Imaging, Biomarker Discovery, Live Dead Assay, ATP Assay, Comparison